Fig. 1From: The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case reportSelected laboratory parameters and clinical interventions. C5b-9 soluble terminal complement complex; CRP C-reactive protein; CRRT continuous renal replacement therapy; IHD intermittent hemodialysis; MAC membrane attack complex; LDH Lactate dehydrogenase; sIL2r soluble interleukin 2 receptorBack to article page